About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Waldencast plc

News headline image
Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
From Waldencast plc
Via GlobeNewswire
Tickers WALD
News headline image
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
From Waldencast plc
Via GlobeNewswire
Tickers WALD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.